Brief: Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules
26/11/2025 21:12
Nov 26 (Reuters) - Tempest Therapeutics Inc TPST.O: TEMPEST ANNOUNCES CLOSING OF UP TO $8.35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK AND CONCURRENT PRIVATE PLACEMENT OF WARRANTS PRICED AT-THE-MARKET UNDER NASDAQ RULES Source text: ID:nGNXx2TqR Further company coverage: TPST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T